News | May 28, 2024
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
